Double-Drug attack on chemo side effect: can two platelet boosters work better than one?
NCT ID NCT06769685
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs—rhTPO and hetrombopag—to raise platelet counts in 100 cancer patients whose platelets dropped due to chemotherapy. Patients are split into two groups based on how low their platelets are, and both groups receive the same drug combo until their platelets reach a safe level. The main goal is to see how quickly platelets recover, with a focus on reducing bleeding and treatment delays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant human thrombopoietin (rhTPO) and hetrombopag
- What this could lead to
- If successful, this could offer a faster, more effective way to raise platelet counts in cancer patients whose platelets drop due to chemotherapy, reducing bleeding risks and treatment delays.
- What could go wrong
- This is a small, early-phase (Phase 2) single-center study with only 100 participants. It is not randomized or blinded, so results may not apply broadly. Side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTIT-CHEMOTHERAPY INDUCED THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinhua Central Hospital
Jinhua, Zhejiang, 321000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.